📊 Cell and #genetherapies offer durable, sometimes curative benefits—but high costs mean payers are still catching up on innovative payment and risk-sharing strategies. Elias Pittos & Joe DePinto explore how payers are navigating these challenges. 👇
www.tandfonline.com/doi/full/10....
#HEOR
tandfonline.com
Cell and gene therapies in managed care: US payer insights on coverage and financial risk
Cell and gene therapies (CGTs) are increasingly transforming the treatment of serious and life-threatening conditions, offering durable and, in some cases, potentially curative benefit. However, hi...
